Literature DB >> 29214566

Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework.

Gareth Baynam1,2,3, Faye Bowman4, Karla Lister4, Caroline E Walker4, Nicholas Pachter5,6,7, Jack Goldblatt6,8, Kym M Boycott9, William A Gahl10,11, Kenjiro Kosaki12, Takeya Adachi13, Ken Ishii13, Trinity Mahede4, Fiona McKenzie6,8, Sharron Townshend8, Jennie Slee8, Cathy Kiraly-Borri8, Anand Vasudevan8, Anne Hawkins8, Stephanie Broley8, Lyn Schofield8, Hedwig Verhoef14,15, Tudor Groza16,17, Andreas Zankl18,19, Peter N Robinson20,21, Melissa Haendel22, Michael Brudno23,24, John S Mattick16,17, Marcel E Dinger16,17, Tony Roscioli16,17, Mark J Cowley16,17, Annie Olry25, Marc Hanauer25, Fowzan S Alkuraya26,27, Domenica Taruscio28, Manuel Posada de la Paz29, Hanns Lochmüller30, Kate Bushby30, Rachel Thompson30, Victoria Hedley30, Paul Lasko31, Kym Mina32,33, John Beilby32, Cynthia Tifft10, Mark Davis32, Nigel G Laing32,34, Daria Julkowska35, Yann Le Cam36, Sharon F Terry37, Petra Kaufmann38, Iiro Eerola39, Irene Norstedt39, Ana Rath25, Makoto Suematsu13, Stephen C Groft38, Christopher P Austin38, Ruxandra Draghia-Akli39, Tarun S Weeramanthri40,41, Caron Molster4, Hugh J S Dawkins42,43,44,45.   

Abstract

Public health relies on technologies to produce and analyse data, as well as effectively develop and implement policies and practices. An example is the public health practice of epidemiology, which relies on computational technology to monitor the health status of populations, identify disadvantaged or at risk population groups and thereby inform health policy and priority setting. Critical to achieving health improvements for the underserved population of people living with rare diseases is early diagnosis and best care. In the rare diseases field, the vast majority of diseases are caused by destructive but previously difficult to identify protein-coding gene mutations. The reduction in cost of genetic testing and advances in the clinical use of genome sequencing, data science and imaging are converging to provide more precise understandings of the 'person-time-place' triad. That is: who is affected (people); when the disease is occurring (time); and where the disease is occurring (place). Consequently we are witnessing a paradigm shift in public health policy and practice towards 'precision public health'.Patient and stakeholder engagement has informed the need for a national public health policy framework for rare diseases. The engagement approach in different countries has produced highly comparable outcomes and objectives. Knowledge and experience sharing across the international rare diseases networks and partnerships has informed the development of the Western Australian Rare Diseases Strategic Framework 2015-2018 (RD Framework) and Australian government health briefings on the need for a National plan.The RD Framework is guiding the translation of genomic and other technologies into the Western Australian health system, leading to greater precision in diagnostic pathways and care, and is an example of how a precision public health framework can improve health outcomes for the rare diseases population.Five vignettes are used to illustrate how policy decisions provide the scaffolding for translation of new genomics knowledge, and catalyze transformative change in delivery of clinical services. The vignettes presented here are from an Australian perspective and are not intended to be comprehensive, but rather to provide insights into how a new and emerging 'precision public health' paradigm can improve the experiences of patients living with rare diseases, their caregivers and families.The conclusion is that genomic public health is informed by the individual and family needs, and the population health imperatives of an early and accurate diagnosis; which is the portal to best practice care. Knowledge sharing is critical for public health policy development and improving the lives of people living with rare diseases.

Entities:  

Keywords:  Community engagement; Information sharing; New knowledge; Policy; Public health; Translation

Mesh:

Year:  2017        PMID: 29214566     DOI: 10.1007/978-3-319-67144-4_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  5 in total

Review 1.  Genomic medicine for undiagnosed diseases.

Authors:  Anastasia L Wise; Teri A Manolio; George A Mensah; Josh F Peterson; Dan M Roden; Cecelia Tamburro; Marc S Williams; Eric D Green
Journal:  Lancet       Date:  2019-08-05       Impact factor: 79.321

Review 2.  Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases.

Authors:  Carla Epps; Ralph Bax; Alysha Croker; Dionna Green; Andrea Gropman; Agnes V Klein; Hannah Landry; Anne Pariser; Marc Rosenman; Michiyo Sakiyama; Junko Sato; Kuntal Sen; Monique Stone; Fumi Takeuchi; Jonathan M Davis
Journal:  Ther Innov Regul Sci       Date:  2022-04-26       Impact factor: 1.337

3.  A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era.

Authors:  Rachel Thompson; Angela Abicht; David Beeson; Andrew G Engel; Bruno Eymard; Emmanuel Maxime; Hanns Lochmüller
Journal:  Orphanet J Rare Dis       Date:  2018-11-26       Impact factor: 4.123

4.  Prevalence of Charcot-Marie-Tooth disease across the lifespan: a population-based epidemiological study.

Authors:  Alice Theadom; Richard Roxburgh; Erin MacAulay; Gina O'Grady; Joshua Burns; Priya Parmar; Kelly Jones; Miriam Rodrigues
Journal:  BMJ Open       Date:  2019-06-14       Impact factor: 2.692

5.  Survey on patients with undiagnosed diseases in Japan: potential patient numbers benefiting from Japan's initiative on rare and undiagnosed diseases (IRUD).

Authors:  Takeya Adachi; Noriaki Imanishi; Yasushi Ogawa; Yoshihiko Furusawa; Yoshihiko Izumida; Yoko Izumi; Makoto Suematsu
Journal:  Orphanet J Rare Dis       Date:  2018-11-20       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.